Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Терапевтические эффекты ингибитора ангиотензинпревращающего фермента фозиноприла
Терапевтические эффекты ингибитора ангиотензинпревращающего фермента фозиноприла
Аронов Д.М. Терапевтические эффекты ингибитора ангиотензинпревращающего фермента фозиноприла. КардиоСоматика. 2015; 2: 56–63.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзорной статье дается характеристика терапевтических особенностей фозиноприла, по-видимому, связанных с тем, что он содержит фосфор. У препарата многочисленный ярко выраженный спектр органотропных эффектов и очень хорошая переносимость и безопасность, позволяющие переводить больных (леченных разными ингибиторами ангиотензинпревращающего фермента), у которых развился сухой кашель, на лечение фозиноприлом. Обсуждаются возможные перспективы применения препарата при нетрадиционной для ингибиторов ангиотензинпревращающего фермента патологии.
Ключевые слова: ингибиторы ангиотензинпревращающего фермента, фозиноприл, моноприл, хроническая сердечная недостаточность.
Key words: ACE inhibitors, fosinopril, monopril, chronic cardiac failure.
Ключевые слова: ингибиторы ангиотензинпревращающего фермента, фозиноприл, моноприл, хроническая сердечная недостаточность.
________________________________________________
Key words: ACE inhibitors, fosinopril, monopril, chronic cardiac failure.
Полный текст
Список литературы
1. Borghi C, Marino P, Zardini P et al. Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS). Am J Hypertens 1997; 10 (10 Pt. 2): 247S–254S.
2. Konermann M, Qdenthal HJ, Altmann C et al. Effect of ACE-inhibitors on left ventricular remodeling after acute anterior or posterior myocardial infarct. Cine-magnetic resonance tomography study. Wien Med Wochenschr 2000; 150 (12): 249–55.
3. Chitnis AS, Aparasu RR, Chen H, Johnson ML. Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J Comp Eff Res 2012; 1 (2): 195–206; doi: 10.2217/cer.12.5.
4. Huang ZB, Deng CY, Lin MH et al. Fosinopril improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats. Naunyn Schmiedeberqs Arch Pharmacol 2014; 387 (11): 1037–44; doi: 10 1007/s 00210-014-1024-y. Epub 2014.
5. Wei M, Gu SM, Zhang YY et al. Effects of pravastatin, fosinopril and their combination on myocardium TNF-alpha expression and ventricular remodeling after myocardial infarction in rats. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33 (5): 444–7.
6. Shrikrishna D, Tanner RJ, Lee JY et al. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD. Chest 2014; 146 (4): 932–40; doi: 10.1378/chest. 13-2483.
7. Zannad F, Chati Z, Guest M, Plat F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Am Heart J. 1998; 136 (4 Pt. 1): 672–80.
8. Saini R, Romanini M, Veqlio F. A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension. Clin Drug Investiq 1998; 15 (1): 21–8.
9. Galatius-Jensen S, Wroblewski H, Emmeluth C et al. Plasma endothelin in congestive heart failure: a predictor of cardiac death. J Card Fail 1996; 2 (2): 71–6.
10. Galatius-Jensen S, Wroblewski H, Emmeluth C et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996; 32 (6): 1148–54.
11. Erhardt L, MacLean A, Igenfritz J et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995; 16 (12): 1892–9.
12. Pilote L, Abrahamowicz M, Eisenberg M et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178 (10): 1303–11.
13. Brouwers FP, Asselbergs FW, Hillege HL et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 2011; 161 (6): 1171–8; doi: 10.1016/j.ahj.2011.03.028. Epub 2011.
14. Marin R, Ruilope LM, Aljama P et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19 (10): 1871–6.
15. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70 (7): 1318–24. Epub 2006.
16. Yu CM, Winq-Hon Lai K, Li PS et al. Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action. J Mol Cell Cardiol 2004; 36 (3): 445–53.
17. Yang S, Li R, Tang L et al. TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibito – fosinopril. Cell Immunol 2013; 285 (l–2): 38–41; doi 10.1016/j.cellimm.2013.08.003. Epub 2013.
18. Tasić IS, Vijalković D, Djordjević D et al. Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients. Srp Arh Celok Lek 2006; 134 (3–4): 106–13.
19. Hosomi N, Mizushige K, Oheama H et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32 (7): 1539–45.
20. Sarro GD, Paola ED, Gratteri S et al. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacol Res 2012; 65 (3): 285–96.
21. Zhang YC, Tang Y, Zhang M et al. Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. Cell Biochem Biophys 2012; 64 (3): 205–11.
2. Konermann M, Qdenthal HJ, Altmann C et al. Effect of ACE-inhibitors on left ventricular remodeling after acute anterior or posterior myocardial infarct. Cine-magnetic resonance tomography study. Wien Med Wochenschr 2000; 150 (12): 249–55.
3. Chitnis AS, Aparasu RR, Chen H, Johnson ML. Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J Comp Eff Res 2012; 1 (2): 195–206; doi: 10.2217/cer.12.5.
4. Huang ZB, Deng CY, Lin MH et al. Fosinopril improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats. Naunyn Schmiedeberqs Arch Pharmacol 2014; 387 (11): 1037–44; doi: 10 1007/s 00210-014-1024-y. Epub 2014.
5. Wei M, Gu SM, Zhang YY et al. Effects of pravastatin, fosinopril and their combination on myocardium TNF-alpha expression and ventricular remodeling after myocardial infarction in rats. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33 (5): 444–7.
6. Shrikrishna D, Tanner RJ, Lee JY et al. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD. Chest 2014; 146 (4): 932–40; doi: 10.1378/chest. 13-2483.
7. Zannad F, Chati Z, Guest M, Plat F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Am Heart J. 1998; 136 (4 Pt. 1): 672–80.
8. Saini R, Romanini M, Veqlio F. A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension. Clin Drug Investiq 1998; 15 (1): 21–8.
9. Galatius-Jensen S, Wroblewski H, Emmeluth C et al. Plasma endothelin in congestive heart failure: a predictor of cardiac death. J Card Fail 1996; 2 (2): 71–6.
10. Galatius-Jensen S, Wroblewski H, Emmeluth C et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996; 32 (6): 1148–54.
11. Erhardt L, MacLean A, Igenfritz J et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995; 16 (12): 1892–9.
12. Pilote L, Abrahamowicz M, Eisenberg M et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178 (10): 1303–11.
13. Brouwers FP, Asselbergs FW, Hillege HL et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 2011; 161 (6): 1171–8; doi: 10.1016/j.ahj.2011.03.028. Epub 2011.
14. Marin R, Ruilope LM, Aljama P et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19 (10): 1871–6.
15. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70 (7): 1318–24. Epub 2006.
16. Yu CM, Winq-Hon Lai K, Li PS et al. Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action. J Mol Cell Cardiol 2004; 36 (3): 445–53.
17. Yang S, Li R, Tang L et al. TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibito – fosinopril. Cell Immunol 2013; 285 (l–2): 38–41; doi 10.1016/j.cellimm.2013.08.003. Epub 2013.
18. Tasić IS, Vijalković D, Djordjević D et al. Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients. Srp Arh Celok Lek 2006; 134 (3–4): 106–13.
19. Hosomi N, Mizushige K, Oheama H et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32 (7): 1539–45.
20. Sarro GD, Paola ED, Gratteri S et al. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacol Res 2012; 65 (3): 285–96.
21. Zhang YC, Tang Y, Zhang M et al. Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. Cell Biochem Biophys 2012; 64 (3): 205–11.
2. Konermann M, Qdenthal HJ, Altmann C et al. Effect of ACE-inhibitors on left ventricular remodeling after acute anterior or posterior myocardial infarct. Cine-magnetic resonance tomography study. Wien Med Wochenschr 2000; 150 (12): 249–55.
3. Chitnis AS, Aparasu RR, Chen H, Johnson ML. Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J Comp Eff Res 2012; 1 (2): 195–206; doi: 10.2217/cer.12.5.
4. Huang ZB, Deng CY, Lin MH et al. Fosinopril improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats. Naunyn Schmiedeberqs Arch Pharmacol 2014; 387 (11): 1037–44; doi: 10 1007/s 00210-014-1024-y. Epub 2014.
5. Wei M, Gu SM, Zhang YY et al. Effects of pravastatin, fosinopril and their combination on myocardium TNF-alpha expression and ventricular remodeling after myocardial infarction in rats. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33 (5): 444–7.
6. Shrikrishna D, Tanner RJ, Lee JY et al. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD. Chest 2014; 146 (4): 932–40; doi: 10.1378/chest. 13-2483.
7. Zannad F, Chati Z, Guest M, Plat F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Am Heart J. 1998; 136 (4 Pt. 1): 672–80.
8. Saini R, Romanini M, Veqlio F. A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension. Clin Drug Investiq 1998; 15 (1): 21–8.
9. Galatius-Jensen S, Wroblewski H, Emmeluth C et al. Plasma endothelin in congestive heart failure: a predictor of cardiac death. J Card Fail 1996; 2 (2): 71–6.
10. Galatius-Jensen S, Wroblewski H, Emmeluth C et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996; 32 (6): 1148–54.
11. Erhardt L, MacLean A, Igenfritz J et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995; 16 (12): 1892–9.
12. Pilote L, Abrahamowicz M, Eisenberg M et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178 (10): 1303–11.
13. Brouwers FP, Asselbergs FW, Hillege HL et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 2011; 161 (6): 1171–8; doi: 10.1016/j.ahj.2011.03.028. Epub 2011.
14. Marin R, Ruilope LM, Aljama P et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19 (10): 1871–6.
15. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70 (7): 1318–24. Epub 2006.
16. Yu CM, Winq-Hon Lai K, Li PS et al. Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action. J Mol Cell Cardiol 2004; 36 (3): 445–53.
17. Yang S, Li R, Tang L et al. TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibito – fosinopril. Cell Immunol 2013; 285 (l–2): 38–41; doi 10.1016/j.cellimm.2013.08.003. Epub 2013.
18. Tasić IS, Vijalković D, Djordjević D et al. Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients. Srp Arh Celok Lek 2006; 134 (3–4): 106–13.
19. Hosomi N, Mizushige K, Oheama H et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32 (7): 1539–45.
20. Sarro GD, Paola ED, Gratteri S et al. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacol Res 2012; 65 (3): 285–96.
21. Zhang YC, Tang Y, Zhang M et al. Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. Cell Biochem Biophys 2012; 64 (3): 205–11.
________________________________________________
2. Konermann M, Qdenthal HJ, Altmann C et al. Effect of ACE-inhibitors on left ventricular remodeling after acute anterior or posterior myocardial infarct. Cine-magnetic resonance tomography study. Wien Med Wochenschr 2000; 150 (12): 249–55.
3. Chitnis AS, Aparasu RR, Chen H, Johnson ML. Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J Comp Eff Res 2012; 1 (2): 195–206; doi: 10.2217/cer.12.5.
4. Huang ZB, Deng CY, Lin MH et al. Fosinopril improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats. Naunyn Schmiedeberqs Arch Pharmacol 2014; 387 (11): 1037–44; doi: 10 1007/s 00210-014-1024-y. Epub 2014.
5. Wei M, Gu SM, Zhang YY et al. Effects of pravastatin, fosinopril and their combination on myocardium TNF-alpha expression and ventricular remodeling after myocardial infarction in rats. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33 (5): 444–7.
6. Shrikrishna D, Tanner RJ, Lee JY et al. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD. Chest 2014; 146 (4): 932–40; doi: 10.1378/chest. 13-2483.
7. Zannad F, Chati Z, Guest M, Plat F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Am Heart J. 1998; 136 (4 Pt. 1): 672–80.
8. Saini R, Romanini M, Veqlio F. A comparison of fosinopril and hydrochlorothiazide with hydrochlorothiazide in non-insulin-dependent diabetes mellitus patients with mild to moderate hypertension. Clin Drug Investiq 1998; 15 (1): 21–8.
9. Galatius-Jensen S, Wroblewski H, Emmeluth C et al. Plasma endothelin in congestive heart failure: a predictor of cardiac death. J Card Fail 1996; 2 (2): 71–6.
10. Galatius-Jensen S, Wroblewski H, Emmeluth C et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996; 32 (6): 1148–54.
11. Erhardt L, MacLean A, Igenfritz J et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995; 16 (12): 1892–9.
12. Pilote L, Abrahamowicz M, Eisenberg M et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178 (10): 1303–11.
13. Brouwers FP, Asselbergs FW, Hillege HL et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 2011; 161 (6): 1171–8; doi: 10.1016/j.ahj.2011.03.028. Epub 2011.
14. Marin R, Ruilope LM, Aljama P et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19 (10): 1871–6.
15. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70 (7): 1318–24. Epub 2006.
16. Yu CM, Winq-Hon Lai K, Li PS et al. Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action. J Mol Cell Cardiol 2004; 36 (3): 445–53.
17. Yang S, Li R, Tang L et al. TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibito – fosinopril. Cell Immunol 2013; 285 (l–2): 38–41; doi 10.1016/j.cellimm.2013.08.003. Epub 2013.
18. Tasić IS, Vijalković D, Djordjević D et al. Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients. Srp Arh Celok Lek 2006; 134 (3–4): 106–13.
19. Hosomi N, Mizushige K, Oheama H et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32 (7): 1539–45.
20. Sarro GD, Paola ED, Gratteri S et al. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacol Res 2012; 65 (3): 285–96.
21. Zhang YC, Tang Y, Zhang M et al. Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. Cell Biochem Biophys 2012; 64 (3): 205–11.
Авторы
Д.М.Аронов
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
aronovdm@mail.ru
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
aronovdm@mail.ru
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
aronovdm@mail.ru
________________________________________________
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
aronovdm@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.